Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic pharmaceutical products. The company portfolio includes anti-platelets, anti-allergens, anti-diabetics, prostaglandins, anti-infectives, non-steroidal anti-inflammatory drugs, quasi-drugs and generic drugs for critical care and for the treatment of circulatory system, digestive system, respiratory system, central peripheral nervous system, cardiovascular diseases, and cancer. Nichi-Iko also offers medicines in various forms including oral disintegration tablets, chewable tablets, gels, capsules, and powders. It has operations in Hong Kong, Thailand, Malaysia, Vietnam, the Philippines, and Singapore. Nichi-Iko is headquartered in Toyama, Japan.
Headquarters
Japan
Address
1-6-21, Sokuruwa, Toyama-Shi, 930-8583
Website
www.nichiiko.co.jp
Telephone
81 76 4322121
No of Employees
2,656
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$1.6B
Nichi-Iko Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Anti-Platelets |
| Anti-Allergens |
| Anti-Diabetics |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Nichi-Iko Pharmaceutical Co Ltd | Towa Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd | Jeil Pharmaceutical Co Ltd | Wakamoto Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | South Korea | South Korea | Japan |
| City | Toyama-Shi | Kadoma-Shi | Seoul | Seoul | Chuo-Ku |
| State/Province | Toyama | Osaka | - | - | Tokyo |
| No. of Employees | 2,656 | 4,298 | 273 | 978 | 292 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yasuhiro Nagafuku | Chairman | Executive Board | - | - |
| Shingo Iwamoto | President; Director | Executive Board | - | - |
| Osamu Mihara | Senior Managing Executive Officer; Director | Executive Board | - | - |
| Susumu Kanda | Director - Managing Executive Officer | Executive Board | - | - |
| Takeshi Shinohara | Director | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward